New Research In
Physical Sciences
Social Sciences
Featured Portals
Articles by Topic
Biological Sciences
Featured Portals
Articles by Topic
- Agricultural Sciences
- Anthropology
- Applied Biological Sciences
- Biochemistry
- Biophysics and Computational Biology
- Cell Biology
- Developmental Biology
- Ecology
- Environmental Sciences
- Evolution
- Genetics
- Immunology and Inflammation
- Medical Sciences
- Microbiology
- Neuroscience
- Pharmacology
- Physiology
- Plant Biology
- Population Biology
- Psychological and Cognitive Sciences
- Sustainability Science
- Systems Biology
Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia
Contributed by Brian J. Druker, October 15, 2019 (sent for review March 26, 2019; reviewed by James DeGregori, Jay L. Hess, and Andrea Sottoriva)

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Significance
A long-held tenet in acute myeloid leukemia (AML) is that multiple genetic events produce a block in the differentiation of primitive myeloblast cells. Using mathematical modeling, we show that, rather than a complete block, even a slight reduction or skewing of the differentiation rate in these cells produces an AML phenotype. We experimentally validated that mature myeloid cells have the same genotype as leukemic blasts, demonstrating that there is not a complete block in differentiation. While targeted differentiation therapies have shown success in isolated subtypes of AML, our findings suggest that maximizing the potential impact of these agents will require discernment of the specific actionable mechanisms underlying reduced or skewed differentiation in genetic subtypes of the disease.
Abstract
Hematopoiesis, the formation of blood cells, involves the hierarchical differentiation of immature blast cells into mature, functional cell types and lineages of the immune system. Hematopoietic stem cells precisely regulate self-renewal versus differentiation to balance the production of blood cells and maintenance of the stem cell pool. The canonical view of acute myeloid leukemia (AML) is that it results from a combination of molecular events in a hematopoietic stem cell that block differentiation and drive proliferation. These events result in the accumulation of primitive hematopoietic blast cells in the blood and bone marrow. We used mathematical modeling to determine the impact of varying differentiation rates on myeloblastic accumulation. Our model shows that, instead of the commonly held belief that AML results from a complete block of differentiation of the hematopoietic stem cell, even a slight skewing of the fraction of cells that differentiate would produce an accumulation of blasts. We confirmed this model by interphase fluorescent in situ hybridization (FISH) and sequencing of purified cell populations from patients with AML, which showed that different leukemia-causing molecular abnormalities typically thought to block differentiation were consistently present in mature myeloid cells such as neutrophils and monocytes at similar levels to those in immature myeloid cells. These findings suggest reduced or skewed, rather than blocked, differentiation is responsible for the development of AML. Approaches that restore normal regulation of hematopoiesis could be effective treatment strategies.
Footnotes
- ↵1To whom correspondence may be addressed. Email: agarwala{at}ohsu.edu or drukerb{at}ohsu.edu.
Author contributions: A.A. and B.J.D. designed research; A.A., W.J.B., D.B.W., S.B.O., and G.F. performed research; A.A., W.J.B., D.B.W., C.A.E., S.B.O., G.F., and B.J.D. analyzed data; and A.A., W.J.B., D.B.W., C.A.E., S.B.O., G.F., and B.J.D. wrote the paper.
Reviewers: J.D., University of Colorado Anschutz Medical Campus; J.L.H., Indiana University School of Medicine; and A.S., The Institute of Cancer Research, London.
Competing interest statement: B.J.D. potential competing interests: The Scientific Advisory Board (SAB): Aileron Therapeutics, ALLCRON, Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Baxalta (inactive), and Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, Third Coast Therapeutics, GRAIL (inactive), and CTI BioPharma (inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VP Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and Oregon Health & Science University (OHSU), and Dana-Farber Cancer Institute (one Merck exclusive license).
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1904091116/-/DCSupplemental.
Published under the PNAS license.
Log in using your username and password
Purchase access
Subscribers, for more details, please visit our Subscriptions FAQ.
Please click here to log into the PNAS submission website.
Citation Manager Formats
Sign up for Article Alerts
Article Classifications
- Biological Sciences
- Cell Biology